Off the wire
• Mourinho takes over Manchester United  • Malaga confirm Ramos as new coach  • City rivals go head to head again for Champions League glory  • Nanjing should not be forgotten: Chinese FM  • Roundup: Zimbabwe maternal mortality drops 32 pct due to improved maternal health care  • New city inaugurated in Tibet  • Microsoft, Facebook to build high-speed transatlantic subsea cable  • Medical devices blamed in 184 deaths last year  • 1st LD Writethru: 6 militants, trooper killed in two separate gunfights in Indian-controlled Kashmir  • Weather forecast for major Chinese cities, regions -- May 27  
You are here: 　 Home

Worldwide Cancer Research to fund four projects at University of Navarra

Xinhua, May 27, 2016 Adjust font size:

The Worldwide Cancer Research (WCR) confirmed Thursday it has granted 715,000 euros (around 800,000 U.S. dollars) to a university in Spain, to find projects on lymphoma, melanoma, lung cancer and breast cancer.

The WCR, an international charity which funds projects in developing strategies for diagnosing and treating the various forms of cancer, granted the fund to the Centre for Applied Medical Research (CIMA) of the University of Navarra, northern Spain.

One of the projects selected will investigate marginal zone lymphoma with the aim of "designing a new effective therapeutic strategy for patients suffering from this lymphoma," according to project leader Dr. Jose Angel Martinez Climent.

A second project will focus on the application of immunotherapy for melanoma patients, while the WCR will also fund a project designed to identify new therapeutic strategies for the most common form of lung cancer: non-small cell lung cancer (CNMP).

Finally, the international foundation will finance a CIMA study on the development of immunological tools to improve breast cancer treatment by combining conventional therapy with immunotherapy.

"We shall study the suitability of several biological compounds in cell cultures and in preclinical breast cancer animal models, which may lead to the application of the most suitable combined therapy for each patient," explained Dr. Ignacio Melero, who will lead the project. Endit